A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

← catalyst calendar

NCT06991257 · readout in 454 d

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase

Phase 2

Status

Recruiting

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

620estimated

Sites

142

Countries

Brazil, Bulgaria, Canada +10

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-06-19

actual

When the study began enrolling

Primary completion

2027-11-16

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-12-14

estimated

The whole study's end, after follow-up

First posted

2025-05-27

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-05-27

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Heart Failure

Interventions

Drug: Placebo
Drug: Low Dose PF-07328948 — also filed as low dose
Drug: Medium Dose PF-07328948 — also filed as medium dose
Drug: High Dose PF-07328948 — also filed as High dose

Primary outcomes

what the primary-completion date above is the date OF

Number of Participants with Clinical Events

measured over 36 weeks

Change From Baseline in 6-Minute Walk Test (6MWD)

measured Baseline, week 36 post-dose

Change From Baseline in Kansas City Cardiomyopathy Questionnaire Overall Total Symptom Score (KCCQ-23 TSS)

measured Baseline, week 36

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed